| P50 | author | Cécile Proust-Lima | Q47006640 |
| | Donna Ankerst | Q58241772 |
| P2093 | author name string | Ning Liu | |
| | Howard M Sandler | |
| | Kyounghwa Bae | |
| | Scott G Williams | |
| | Jeremy M G Taylor | |
| | Cécile Proust-Lima | |
| | Larry L Kestin | |
| P2860 | cites work | Dose response in prostate cancer with 8-12 years' follow-up | Q74816597 |
| | Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis | Q77424028 |
| | PSA failure and the risk of death in prostate cancer patients treated with radiotherapy | Q80944666 |
| | Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer | Q80944681 |
| | Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy | Q80983248 |
| | Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy | Q81280205 |
| | Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy | Q81801781 |
| | Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V | Q81814923 |
| | Random-effects models for longitudinal data | Q28279619 |
| | Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer | Q31110019 |
| | Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups | Q33245593 |
| | Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference | Q34541651 |
| | What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice. | Q39124612 |
| | Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower | Q39722492 |
| | Individualized predictions of disease progression following radiation therapy for prostate cancer. | Q40449850 |
| | Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy | Q40886892 |
| | Does age influence the behaviour of localized prostate cancer? | Q44199125 |
| | Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. | Q44237145 |
| | Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer | Q45081057 |
| | Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate | Q46444541 |
| | Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? | Q46540237 |
| | Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study | Q46718480 |
| | Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant a | Q46889564 |
| | Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy | Q53864292 |
| | Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer | Q71634094 |
| | Prostate-specific antigen and radiation therapy for clinically localized prostate cancer | Q71693278 |
| | Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations | Q71975341 |
| | Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy | Q73094454 |
| | Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel | Q73383408 |
| | Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer | Q74144712 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| | prostate cancer | Q181257 |
| P304 | page(s) | 782-791 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts | |
| P478 | volume | 72 | |